Traws Pharma Director Departs, New Director Appointed
Ticker: TRAW · Form: 8-K · Filed: Jul 3, 2025 · CIK: 1130598
| Field | Detail |
|---|---|
| Company | Traws Pharma, Inc. (TRAW) |
| Form Type | 8-K |
| Filed Date | Jul 3, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-change, management
TL;DR
Traws Pharma board shakeup: Dr. Jonathan Macarthur out, Dr. David Macarthur in.
AI Summary
Traws Pharma, Inc. announced on July 2, 2025, the departure of Director Dr. Jonathan R. T. Macarthur and the appointment of Dr. David J. E. Macarthur as a new director. The company also reported on compensatory arrangements for its officers.
Why It Matters
Changes in board composition can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: low — The filing reports routine board changes and compensatory arrangements, which are standard corporate disclosures and do not inherently indicate elevated risk.
Key Players & Entities
- Traws Pharma, Inc. (company) — Registrant
- Dr. Jonathan R. T. Macarthur (person) — Departing Director
- Dr. David J. E. Macarthur (person) — Appointed Director
- July 2, 2025 (date) — Date of earliest event reported
FAQ
Who is the departing director and when did their departure become effective?
Dr. Jonathan R. T. Macarthur departed as a director, with the earliest event reported on July 2, 2025.
Who is the newly appointed director?
Dr. David J. E. Macarthur was appointed as a new director.
What is the company's primary business?
Traws Pharma, Inc. is in the Pharmaceutical Preparations industry (SIC code 2834).
What is the company's state of incorporation?
Traws Pharma, Inc. is incorporated in Delaware.
What is the company's fiscal year end?
The company's fiscal year ends on December 31.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 3, 2025 by Dr. Jonathan R. T. Macarthur regarding Traws Pharma, Inc. (TRAW).